^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG CLASS:

PLA2 inhibitor

15d
When Immunosuppression Fails: Cardiac Myxoma Mimicking Systemic Lupus Erythematosus Flare With a Diagnostic Delay. (PubMed, Cureus)
During this period, she received escalating immunosuppression with corticosteroids, mycophenolate, and cyclophosphamide...Immunosuppression was de-escalated to hydroxychloroquine alone with no recurrence at 14-month follow-up...Cardiac myxomas produce IL-6 in the majority of patients (frequency >75%), and systemic constitutional signs are observed in a substantial proportion, though not uniformly. This can produce IL-6-mediated inflammation indistinguishable from autoimmune flares.
Journal
|
IL6 (Interleukin 6)
|
cyclophosphamide • hydroxychloroquine
26d
The Dual Role of Autophagy in Lung Cancer: From Molecular Mechanisms to Metabolic Regulation and Targeted Therapy Strategies. (PubMed, Front Biosci (Landmark Ed))
In addition, we critically appraise clinical attempts to modulate autophagy (e.g., with chloroquine/hydroxychloroquine (CQ/HCQ) or mTOR inhibitors), outlining reasons for mixed outcomes and proposing practical solutions for future trials. Finally, potential targeted therapeutic strategies are discussed, including approaches to inhibit cytoprotective autophagy and strategies to induce autophagy-dependent cell death using novel small-molecule activators. Collectively, the evidence supports a model in which precise, context-aware modulation of autophagy-guided by pharmacodynamic (PD) biomarkers and molecular stratification-will be key to improving outcomes in lung cancer.
Review • Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • STK11 (Serine/threonine kinase 11) • BECN1 (Beclin 1)
|
hydroxychloroquine • chloroquine phosphate
1m
LES-HYDROXY: Description of Compliance With Hydroxychloroquine Treatment in Patients With Systemic Lupus Erythematosus (clinicaltrials.gov)
P=N/A, N=102, Completed, University Hospital, Toulouse | Recruiting --> Completed | N=50 --> 102
Trial completion • Enrollment change • Compliance
|
hydroxychloroquine
1m
Imaging Reactive Oxygen Species with L-012 Reveals Neutrophil Extracellular Trap Formation in Pancreatic Ductal Adenocarcinoma. (PubMed, Antioxidants (Basel))
In vivo analyses using subcutaneous and spontaneous murine PDAC models revealed elevated ROS in tumors, which were significantly reduced upon genetic deletion of host MPO or peptidyl arginine deiminase 4, an essential enzyme for NET formation, or after treatment with hydroxychloroquine, a NET inhibitor...Importantly, ROS levels correlated strongly with NET formation in patient samples. These findings reveal a bidirectional relationship between ROS and NETs and highlight the potential utility of L-012- and [18F]4FN-based PET imaging for monitoring NET-associated inflammation in PDAC in vivo.
Journal
|
MPO (Myeloperoxidase)
|
hydroxychloroquine
2ms
REAGIR II: Rose Bengal Electromagnetic Activation With Green Light for Infection Reduction II (clinicaltrials.gov)
P3, N=60, Active, not recruiting, University of California, San Francisco | Recruiting --> Active, not recruiting
Enrollment closed
2ms
CPC12 An unusual case of paraneoplastic sarcoid presenting as dactylitis. (PubMed, Br J Dermatol)
A diagnosis of sarcoid dactylitis was made and treatment commenced with a reducing course of prednisolone 40 mg daily, along with hydroxychloroquine 200 mg twice daily...The radiological findings can therefore aid diagnosis. Our case highlights the rare initial presentation of dactylitis as a manifestation of paraneoplastic sarcoid.
Journal
|
IFNG (Interferon, gamma) • IL2 (Interleukin 2)
|
hydroxychloroquine
2ms
Using Hydroxychloroquine (HCQ) to Treat Steatohepatitis (clinicaltrials.gov)
P3, N=210, Recruiting, National Taiwan University Hospital
New P3 trial
|
hydroxychloroquine
2ms
Nrf2 modulates macrophage foam cells senescence and autophagy activation. (PubMed, Toxicol Mech Methods)
Furthermore, inhibiting the late stage of autophagy with hydroxychloroquine (HCQ) decreased cell viability, while early-stage autophagy inhibition using 3-Methyladenine (3-MA) had no significant effect. These results highlight the critical role of Nrf2 in controlling foam cell development, senescence, and autophagic processes, giving valuable insights into potential therapeutic targets for atherosclerosis.
Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • MMP9 (Matrix metallopeptidase 9)
|
hydroxychloroquine
2ms
Repurposing Antimalarials for Oral Cancer: Selective Efficacy of Hydroxychloroquine on Gingival Squamous Cell Carcinoma. (PubMed, Int J Mol Sci)
Chloroquine (CQ) and hydroxychloroquine (HCQ) have shown potential owing to their roles in autophagy modulation and immune regulation. Gene expression profiling and flow-cytometry analyses revealed cell-type-specific differences in apoptosis, mitochondrial potential, and DNA damage, suggesting HCQ's selective anti-tumor potential in gingival carcinoma. These findings highlight HCQ as a repurposed adjuvant therapy that modulates autophagy and apoptosis to enhance chemosensitivity in oral cancer.
Journal
|
CA9 (Carbonic anhydrase 9) • TFEB (Transcription Factor EB 2)
|
hydroxychloroquine • chloroquine phosphate
3ms
Doxycycline Boosted Therapy in Lyme Borreliosis: DoBo Study. (clinicaltrials.gov)
P4, N=50, Not yet recruiting, Radboud University Medical Center
New P4 trial
|
hydroxychloroquine
3ms
ICoN-1 Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension (clinicaltrials.gov)
P3, N=132, Terminated, Mannkind Corporation | N=234 --> 132 | Trial completion date: Dec 2028 --> Nov 2025 | Recruiting --> Terminated | Trial primary completion date: Aug 2026 --> Nov 2025; Futility
Enrollment change • Trial completion date • Trial termination • Trial primary completion date
3ms
Proteins linked to type II interferon response in Sjögren's disease: novel indicators for disease monitoring and predicting treatment response to leflunomide and hydroxychloroquine combination therapy. (PubMed, Front Immunol)
These data support a significant role for a type II IFN-associated immune response in SjD pathogenesis, which is targeted by LEF/HCQ. Proteins associated with type II IFN-driven immune responses hold potential to monitor disease activity and predict treatment response.
Clinical • Journal • IO biomarker
|
IFNG (Interferon, gamma) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • CD70 (CD70 Molecule) • CXCL11 (C-X-C Motif Chemokine Ligand 11)
|
hydroxychloroquine • leflunomide